Search results
Results from the WOW.Com Content Network
Chong Kun Dang (Korean: 종근당) is a South Korean multinational pharmaceutical company headquartered in Seoul. Founded as Goongbon Pharmacy under Japanese rule in 1941, it was renamed in 1946 and has since become one of the largest pharmaceutical manufacturers in the country.
The absolute bioavailability of lobeglitazone is about 95% in rat. [1] In human, the mean steady state clearance (CL ss /F) was 1.13 L/h across in 1 to 4 mg dose range. In the dose range, the mean half-life was 10.3 h. [2]
The drug was approved in September 2020 in Japan for anemia associated with CKD [2] and is currently in clinical development in the United States and South Korea. [3] The drug is being developed by Japan Tobacco and JW Pharmaceutical. [4]
HONG KONG (Reuters) -Private equity firm Blackstone Inc is nearing a deal to sell its controlling stake in South Korean wholesale drug distributor Geo-Young to North Asian buyout fund MBK Partners ...
Pages in category "Pharmaceutical companies of South Korea" The following 7 pages are in this category, out of 7 total. This list may not reflect recent changes. A.
U.S.-based Blackstone Group said on Tuesday it had agreed to acquire South Korean wholesale drug distributor Geo-Young in a deal with the company's founder. Blackstone did not disclose the value ...
Finerenone, marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. [8]
Vifor Fresenius Medical Care Renal Pharma (VFMCRP), the joint company with Fresenius Medical Care since 2010, gives CSL Vifor access to a network of dialysis centers. [23] It is active in the treatment of chronic kidney disease (CKD), [31] chronic kidney disease-associated pruritus, [32] renal anemia [33] and hyperphosphatemia. [23]